Introduction {#sec1_1}
============

Strongyloidiasis is a common parasitic infection caused by *Strongyloides stercoralis*. it is endemic in tropical and subtropical countries including Southeast Asia, sub-Saharan Africa, South America, and Eastern Europe with prevalence rates reported as high as 30\$. Under immunological conditions, intestinal infection with this nematode is usually associated with asymptomatic carrier status. However, disseminated strongyloidiasis occurs with immune suppression and has been studied in patients with organ transplantation, leukaemia, and human immunodeficiency virus. While parasite-related glomerular diseases have been studied, strongyloidiasis-related glomerulopathy has not been well documented. Several case reports have suggested a causal relationship between strongyloidiasis and nephrotic syndrome but the relationship remains controversial. We review the literature and report a case of disseminated strongyloidiasis in a patient with minimal change nephrotic syndrome treated with high-dose corticosteroids. The remission of nephrotic syndrome after treatment of strongyloidiasis postulates that the nephrotic syndrome could have been related to the Strongyloides immune complex deposition.

Case Report {#sec1_2}
===========

A 67-year-old Hispanic male with medical history of hypertension, who was originally from Puerto Rico but had moved to the USA in adulthood, presented with nausea, bloating, and generalized oedema for 1 month in December 2014. He did not have fever, chills, cough, or diarrhoea. He was a non-smoker, and did not drink alcohol or use illicit drugs.

On initial physical examination, he was afebrile, with a blood pressure of 168/100 mm Hg and heart rate of 80 beats/min. He had periorbital swelling and bilateral lower extremity oedema. His cardiovascular, respiratory, abdominal, and neurological examinations were otherwise unremarkable.

Initial laboratory tests showed a leucocyte count of 12,800/µL with 15.5\$ eosinophilia, serum creatinine of 2.2 mg/dL, serum albumin of 2.3 g/dL, and total proteinuria of 11.1 g/day. HB~s~ antigen and anti-HCV antibody were negative and abdominal ultrasound showed normal-sized kidneys. Electrocardiogram and chest radiograph were normal.

A percutaneous renal biopsy was performed. Light microscopy revealed 13 glomeruli. Electron microscopy revealed complete podocyte foot process effacement and immunofluorescence revealed linear, segmental to global GBM staining for IgG and kappa of unclear significance. At this point, idiopathic minimal change disease was suspected, as no clear aetiology or inciting factor was identified. The patient was started on prednisone 80 mg daily and treatment resulted in improvement of proteinuria to 0.47 g/day by day 33.

A month following initiation of corticosteroids, the patient was evaluated for loss of appetite, fatigue, minimally productive cough, vomiting, and diarrhoea. The diarrhoea was non-bloody and watery, occurring after meals. Chest radiograph revealed a new interstitial reticulonodular pattern of unclear significance. Abdominal radiograph revealed abnormal gas collection thought to be due to small bowel obstruction that was managed conservatively. Due to the development of melena, he underwent diagnostic endoscopy which revealed oedematous gastric and duodenal mucosa (Fig. [1](#F1){ref-type="fig"}). Biopsy of lesions showed chronic active gastritis with the presence of larvae/nematode within the mucosa, consistent with diagnosis of strongyloidiasis (Fig. [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). The patient was treated with 200 µg/kg ivermectin for 5 days and his diarrhoea promptly improved. No ova or parasites were noted in the stool 2 weeks later. Based on a literature review, it was hypothesized that his nephrotic syndrome and minimal change disease may have been in fact caused by Strongyloides and only unmasked during steroid therapy. It was therefore decided that his proteinuria would be closely followed off steroids, and did actually resolve 3 months after infection eradication.

Discussion {#sec1_3}
==========

*S. stercoralis* is usually associated with an asymptomatic carrier state. However, under certain conditions, most notably a compromise of host immunity, fulminant disease may develop with greater than 50\$ mortality despite adequate treatment \[[@B1]\]. In symptomatic patients, the most common presentations are fever, nausea, vomiting, and diarrhoea. In disseminated disease, the nematode can affect virtually every organ, including the brain, lungs, and kidneys \[[@B2]\].

Cases of strongyloidiasis-associated glomerulopathy have rarely been reported. An extensive review of the medical literature has identified 7 other cases of strongyloidiasis associated with nephrotic syndrome (Table [1](#T1){ref-type="table"}). In 7 out of 8 cases, the patient\'s initial presentation was with features of nephrotic syndrome, and all patients were found to have minimal change disease on renal biopsy. In the majority of cases, nephrotic syndrome was diagnosed first, and following the initiation of steroids, only then was Strongyloides unmasked. Corticosteroid therapy could alter immunological mechanisms and play and important role in the abrupt exacerbation of Strongyloides. Interestingly, Hsieh et al. \[[@B3]\] reported a patient with initial manifestations strongly related to Strongyloidiasis who later developed nephrotic syndrome. Heavy proteinuria resolved following treatment with anthelmintic therapy without use of steroids, suggestive of a possible causal relationship between *S. stercoralis* infection and minimal change disease. The pathogenesis of Strongyloides-associated glomerulopathy is postulated to be due to immune complex deposition, as supported by the fact that the Strongyloides antigen has been demonstrated in renal biopsy tissue \[[@B4]\].

A common finding among the reported cases is the presence of peripheral eosinophilia. In our patient, he had eosinophilia but this was not a persistent finding. Studies have shown that eosinophilia is not always present, usually fluctuating and even absent in more than 50\$ of patients with severe infection \[[@B5]\]. Hence, a high index of suspicion is required for prompt diagnosis.

The diagnosis of Strongyloides can be confirmed by the presence of larvae in stool or duodenal aspirate. Duodenal biopsy usually shows blunting of the villi and invasion by the parasite and ova. The standard first-line therapy for Strongyloides infection includes thiabendazole, ivermectin, and albendazole, with comparable eradication rates \[[@B6], [@B7], [@B8]\].

Conclusions {#sec1_4}
===========

When a patient who resides in an endemic part of the world presents with nephrotic syndrome, a thorough review of systems should be done to rule out active Strongyloides infection. Our literature review suggests that active symptoms are only unmasked after steroids are initiated, so ongoing monitoring of any new or chronic symptoms is vital, especially as the usual treatment of nephrotic syndrome can cause lethal disseminated Strongyloides infection. To date, there is 1 published case of symptomatic Strongyloides with subsequent development of nephrotic syndrome that remitted with antibiotic treatment, and multiple other cases where infectious symptoms were unmasked by nephrotic syndrome treatment. Due to this increasingly reported association, more research is warranted to investigate for a clear causal relationship.
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Clinical characteristics of strongyloidiasis-associated nephropathy in the literature review

  Author                             Age, years/sex               Prior diagnosis of strongyloidiasis   Initial presenting symptoms        Duration of steroid use   Manifestations of strongyloidiasis    Kidney biopsy                            Antihelmintic therapy   Outcome
  ---------------------------------- ---------------------------- ------------------------------------- ---------------------------------- ------------------------- ------------------------------------- ---------------------------------------- ----------------------- -----------
  Present case                       67/M                         No                                    Generalized oedema                 1 month                   Nausea, vomiting, diarrhoea           MCD                                      Ivermectin              Remission
                                                                                                                                                                                                                                                                            
  Miyazaki et al. \[[@B9]\], 2010    69/M                         No                                    Generalized oedema                 \>4 months                Diarrhoea, weight loss                MCD                                      Ivermectin              Died
                                                                                                                                                                                                                                                                            
  Hsieh et al. \[[@B3]\], 2006       72/M                         Yes                                   Cough, abdominal pain, diarrhoea   Nil                       Presenting symptoms                   MCD                                      Ivermectin              Remission
                                                                                                                                                                                                                                                                            
  Morimoto et al. \[[@B10]\], 2002   60/F                         No                                    Generalized oedema                 2 months                  Vomiting, paralytic ileus             MCD                                      \-                      Died
                                                                                                                                                                                                                                                                            
  Yee et al. \[[@B11]\], 1999        55/M                         No                                    Generalized oedema                 6 weeks                   Epigastralgia, vomiting, diarrhoea    MCD                                      Thiabendazole           Remission
                                                                                                                                                                                                                                                                            
  Wong et al. \[[@B12]\], 1998       42/F                         No                                    Generalized oedema                 6 weeks                   Brain abscess, gram-negative sepsis   (Biopsy done 4 months after treatment)                           
                                                                                                                                                                                                                                                                            
  MCD                                Thiabendazole, albendazole   Remission                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                            
  Mori et al. \[[@B13]\], 1998       62/M                         No                                    Generalized oedema                 1 month                   Epigastralgia, paralytic ileus        MCD                                      Thiabendazole           Remission

MCD, minimal change disease.
